Trial Outcomes & Findings for A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT) (NCT NCT03452488)

NCT ID: NCT03452488

Last Updated: 2024-10-01

Results Overview

Gait speed was measured using the 400 MW test, which measured how long it took the participant to walk a distance of 400 meters. Missing data imputed using adjusted Bayesian Multiple Imputation (MI) methods for Non-Completers who failed to perform the Test feasibility and Multiple Imputation for participants who without data on on-Site visit. Data up to 9 months was used where 6 months data were unavailable for participants enrolled during the COVID-19 pandemic.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

233 participants

Primary outcome timeframe

Baseline and 6 Months

Results posted on

2024-10-01

Participant Flow

Participants were enrolled from 19 centers in the United States and 3 centers in Belgium.

Participant milestones

Participant milestones
Measure
Placebo
Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
175mg BIO101
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
350mg BIO101
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Overall Study
STARTED
81
76
76
Overall Study
COMPLETED
70
64
69
Overall Study
NOT COMPLETED
11
12
7

Reasons for withdrawal

Reasons for withdrawal
Measure
Placebo
Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
175mg BIO101
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
350mg BIO101
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Overall Study
Adverse Event
4
6
1
Overall Study
Death
0
0
1
Overall Study
Lost to Follow-up
1
2
0
Overall Study
PI Decision
1
0
0
Overall Study
Withdrew consent
4
2
2
Overall Study
Withdraw due to the COVID-19 outbreak
1
0
1
Overall Study
Other
0
2
2

Baseline Characteristics

A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Placebo
n=81 Participants
Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
175mg BIO101
n=75 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
350mg BIO101
n=76 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Total
n=232 Participants
Total of all reporting groups
Age, Continuous
75.5 Years
STANDARD_DEVIATION 7.12 • n=99 Participants
76.2 Years
STANDARD_DEVIATION 7.10 • n=107 Participants
76.3 Years
STANDARD_DEVIATION 6.38 • n=206 Participants
76.0 Years
STANDARD_DEVIATION 6.86 • n=7 Participants
Sex: Female, Male
Female
44 Participants
n=99 Participants
37 Participants
n=107 Participants
38 Participants
n=206 Participants
119 Participants
n=7 Participants
Sex: Female, Male
Male
37 Participants
n=99 Participants
38 Participants
n=107 Participants
38 Participants
n=206 Participants
113 Participants
n=7 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
Asian
13 Participants
n=99 Participants
13 Participants
n=107 Participants
14 Participants
n=206 Participants
40 Participants
n=7 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
Black or African American
3 Participants
n=99 Participants
7 Participants
n=107 Participants
1 Participants
n=206 Participants
11 Participants
n=7 Participants
Race (NIH/OMB)
White
65 Participants
n=99 Participants
55 Participants
n=107 Participants
61 Participants
n=206 Participants
181 Participants
n=7 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
0 Participants
n=7 Participants
Region of Enrollment
Belgium
7 participants
n=99 Participants
6 participants
n=107 Participants
7 participants
n=206 Participants
20 participants
n=7 Participants
Region of Enrollment
United States
74 participants
n=99 Participants
69 participants
n=107 Participants
69 participants
n=206 Participants
212 participants
n=7 Participants

PRIMARY outcome

Timeframe: Baseline and 6 Months

Population: Full Analysis Set: The Full Analysis Set (FAS) population consists of randomized participants, excluding participants who failed to take at least one dose of trial medication and had a very early withdrawal (first week after randomization) definitely not related to study medication and lacked any post randomization data. Participants with data available were included. One participant randomized but not treated with 175 mg BIO101.

Gait speed was measured using the 400 MW test, which measured how long it took the participant to walk a distance of 400 meters. Missing data imputed using adjusted Bayesian Multiple Imputation (MI) methods for Non-Completers who failed to perform the Test feasibility and Multiple Imputation for participants who without data on on-Site visit. Data up to 9 months was used where 6 months data were unavailable for participants enrolled during the COVID-19 pandemic.

Outcome measures

Outcome measures
Measure
Placebo
n=79 Participants
Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
175mg BIO101
n=75 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
350mg BIO101
n=76 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Change From Baseline to 6 Months in Gait Speed for 400 Meter Walking (MW) Test
Gait Speed based on Mixed Effect Model
0.0093 Meter/Second (m/s)
Interval -0.0369 to 0.0556
0.0457 Meter/Second (m/s)
Interval -0.0014 to 0.0927
0.0478 Meter/Second (m/s)
Interval 0.005 to 0.0907
Change From Baseline to 6 Months in Gait Speed for 400 Meter Walking (MW) Test
Gait Speed Based on Adjusted Bayesian Imputation
-0.2886 Meter/Second (m/s)
Interval -0.3641 to -0.2132
-0.2543 Meter/Second (m/s)
Interval -0.3347 to -0.1738
-0.2014 Meter/Second (m/s)
Interval -0.279 to -0.1238
Change From Baseline to 6 Months in Gait Speed for 400 Meter Walking (MW) Test
MI + Adjusted Bayesian Imputation
-0.0188 Meter/Second (m/s)
Interval -0.0743 to 0.0366
-0.0066 Meter/Second (m/s)
Interval -0.0547 to 0.0415
0.0500 Meter/Second (m/s)
Interval -0.0013 to 0.1013

SECONDARY outcome

Timeframe: Baseline and 6 Months

Population: Full Analysis Set: Population consists of randomized participants, excluding participants who failed to take at least one dose of trial medication and had a very early withdrawal (first week after randomization) definitely not related to study medication and lacked any post randomization data. Participants with data available were included.

The Physical Function Domain (PF-10) of the SF-36 assesses an individual's perceived physical functioning and limitations in various activities. It consists of ten items that ask about a person's ability to perform different physical activities and tasks. Scores on the PF-10 range from 0 to 100 where 100 indicates no physical limitations. Missing data imputed using adjusted Bayesian MI methods. Data up to 9 month was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Outcome measures

Outcome measures
Measure
Placebo
n=79 Participants
Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
175mg BIO101
n=75 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
350mg BIO101
n=74 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Change From Baseline to 6 Months in Short Form-36 (SF-36) 10 Item Physical Function Domain (PF-10) Sub-score
Analysis based on Mixed Effect Model for MMRM
7.3 score on a scale
Interval 2.4 to 12.3
7.1 score on a scale
Interval 1.9 to 12.3
7.1 score on a scale
Interval 2.2 to 12.1
Change From Baseline to 6 Months in Short Form-36 (SF-36) 10 Item Physical Function Domain (PF-10) Sub-score
Based on Adjusted Bayesian Imputation
1.4 score on a scale
Interval -4.8 to 7.6
4.0 score on a scale
Interval -2.1 to 10.1
4.1 score on a scale
Interval -1.7 to 9.8

SECONDARY outcome

Timeframe: Baseline and 6 Months

Population: Full Analysis Set: Population consists of randomized participants, excluding participants who failed to take at least one dose of trial medication and had a very early withdrawal (first week after randomization) definitely not related to study medication and lacked any post randomization data. Participants with data available were included.

Handgrip strength was a commonly used measure of upper body skeletal muscle function and had been widely used as a general indicator of frailty with predictive validity for both mortality and functional limitations. Participants were instructed to stand upright and with the dynamometer beside them but not against their body. Strength was measured three times for both hands. The highest value of all 3 attempts was kept for further analysis. Grip strength was measured in the dominant hand using a hydraulic grip strength dynamometer. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Outcome measures

Outcome measures
Measure
Placebo
n=74 Participants
Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
175mg BIO101
n=69 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
350mg BIO101
n=69 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Change From Baseline to 6 Months in Handgrip Strength Test
Handgrip strength Test at Month 6 (dominant hand)
-0.709 kilograms (Kg)
Interval -2.902 to 1.484
-1.601 kilograms (Kg)
Interval -3.935 to 0.733
0.590 kilograms (Kg)
Interval -1.533 to 2.712
Change From Baseline to 6 Months in Handgrip Strength Test
Handgrip strength test at month 6 (Left hand)
-0.860 kilograms (Kg)
Interval -2.852 to 1.131
-1.597 kilograms (Kg)
Interval -3.766 to 0.573
0.319 kilograms (Kg)
Interval -1.626 to 2.264
Change From Baseline to 6 Months in Handgrip Strength Test
Handgrip strength test at month 6 (Right hand)
-0.842 kilograms (Kg)
Interval -3.098 to 1.414
-1.664 kilograms (Kg)
Interval -3.993 to 0.665
0.865 kilograms (Kg)
Interval -1.262 to 2.992
Change From Baseline to 6 Months in Handgrip Strength Test
Based on Multiple Imputation (dominant hand)
0.145 kilograms (Kg)
Interval -2.27 to 2.561
0.297 kilograms (Kg)
Interval -2.194 to 2.788
0.663 kilograms (Kg)
Interval -1.822 to 3.148

SECONDARY outcome

Timeframe: Baseline and 6 Months

Population: Full Analysis Set: Population consists of randomized participants, excluding participants who failed to take at least one dose of trial medication and had a very early withdrawal (first week after randomization) definitely not related to study medication and lacked any post randomization data. Participants with data available were included.

DEXA scans provided accurate measurements of body composition, recording fat and lean mass distribution throughout the entire body. Foundation of National Health Institute (FNIH) project report recommended ALM alone was used to measure gender-specific low muscle mass. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Outcome measures

Outcome measures
Measure
Placebo
n=58 Participants
Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
175mg BIO101
n=53 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
350mg BIO101
n=57 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Change From Baseline to 6 Months in Appendicular Lean Body Mass (ALM) Based on Dual-energy X-ray Absorptiometry (DEXA) Measurements
-0.276 Kg
Interval -0.911 to 0.359
-0.283 Kg
Interval -0.944 to 0.378
0.068 Kg
Interval -0.496 to 0.632

SECONDARY outcome

Timeframe: Baseline and 6 Months

Population: Full Analysis Set: Population consists of randomized participants, excluding participants who failed to take at least one dose of trial medication and had a very early withdrawal (first week after randomization) definitely not related to study medication and lacked any post randomization data. Participants with rate of response for completing 400 MW test were included in the analysis.

A responder was defined as an improvement (increase) of 0.1 m/s or more in 400MW gait speed test compared to baseline. A non-responder was defined as a participant that was not a responder. Participants with a missing value at the visit and/or missing baseline value were considered as non-responders. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Outcome measures

Outcome measures
Measure
Placebo
n=81 Participants
Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
175mg BIO101
n=75 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
350mg BIO101
n=76 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Rate of Response for Completing 400 MW Test After 6 Months
Responder
4 Participants
9 Participants
11 Participants
Rate of Response for Completing 400 MW Test After 6 Months
Non-responder
77 Participants
66 Participants
65 Participants

SECONDARY outcome

Timeframe: Baseline and 6 Months

Population: Full Analysis Set: Population consists of randomized participants, excluding participants who failed to take at least one dose of trial medication and had a very early withdrawal (first week after randomization) definitely not related to study medication and lacked any post randomization data. This data represents Knee Extension of Highest Reading from all Degrees. Participants with data available were included.

Isometric knee extension torque was measured with a knee extension dynamometer chair. The participants were positioned in an upright position, with straps to affix the hips to the chair and the ankle to a force or torque transducer at the knee angle of 90°. Lever arm length was recorded as the distance between the knee axis of rotation and the middle of the pad. Knee extension was measured using the maximum peak torque measurement Newton meter (Nm) for 60°/s, 90°/s and 180°/s for the tested leg (either right or left). The Knee extension torque was obtained either directly or by multiplying recorded peak force with the lever arm length. The assay with the highest torque output was taken for analyses. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Outcome measures

Outcome measures
Measure
Placebo
n=8 Participants
Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
175mg BIO101
n=6 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
350mg BIO101
n=10 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Change From Baseline to 6 Months in Muscle Strength Based on Knee Extension
0.484 Newton meter (Nm)
Interval -18.088 to 19.056
-1.092 Newton meter (Nm)
Interval -21.833 to 19.649
-4.515 Newton meter (Nm)
Interval -17.889 to 8.858

SECONDARY outcome

Timeframe: Baseline and 6 Months

Population: Full Analysis Set: Population consists of randomized participants, excluding participants who failed to take at least one dose of trial medication and had a very early withdrawal (first week after randomization) definitely not related to study medication and lacked any post randomization data. Participants with data available were included.

The SPPB was a series of tests designed to examine physical movements. The chair stands tests involved standing from a chair a number of times to test leg strength. Each performance measures were assigned a score ranging from 0 to 4, with 4 indicating the highest level of performance and 0 the inability to complete the test. The time to complete the task was recorded. The time required to perform five chair stands was scored as follows: ≥ 16.70 sec = 1; 13.70 to 16.69 sec = 2; 11.20 to 13.69 sec = 3; ≤ 11.19 = 4. A score of 0 was assigned to participants unable to perform the task. A summary score ranging from 0 (worst performers) to 12 (best performers) was calculated by adding sub scores from the chair stands test. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Outcome measures

Outcome measures
Measure
Placebo
n=29 Participants
Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
175mg BIO101
n=31 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
350mg BIO101
n=37 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Change From Baseline to 6 Months in Time for Five Chair Stands as Part of the Short Physical Performance Battery (SPPB) Assessment
-3.857 Seconds
Interval -6.024 to -1.69
-2.572 Seconds
Interval -4.721 to -0.422
-1.206 Seconds
Interval -3.135 to 0.724

SECONDARY outcome

Timeframe: Baseline and 6 Months

Population: Full Analysis Set: Population consists of randomized participants, excluding participants who failed to take at least one dose of trial medication and had a very early withdrawal (first week after randomization) definitely not related to study medication and lacked any post randomization data. Participants with data available were included.

The 6MWT was a test for functional exercise capacity and involved measuring the distance a participant could cover within the allotted time of 6 minutes. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Outcome measures

Outcome measures
Measure
Placebo
n=33 Participants
Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
175mg BIO101
n=33 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
350mg BIO101
n=37 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Change From Baseline to 6 Months in Distance in the 6-Minute Walk Test (6MWT)
-9.879 Meters
Interval -37.089 to 17.33
-7.166 Meters
Interval -36.559 to 22.228
15.728 Meters
Interval -10.981 to 42.436

SECONDARY outcome

Timeframe: Baseline and 6 Months

Population: Full Analysis Set: Population consists of randomized participants, excluding participants who failed to take at least one dose of trial medication and had a very early withdrawal (first week after randomization) definitely not related to study medication and lacked any post randomization data. Participants with data available were included.

The PAT-D was a disability questionnaire which asked respondents how much difficulty they had with a range of activities with functioning. PAT-D scores range from 1 (worst) to 5 (best). Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Outcome measures

Outcome measures
Measure
Placebo
n=38 Participants
Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
175mg BIO101
n=39 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
350mg BIO101
n=45 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Change From Baseline to 6 Months in Pepper Assessment Tool for Disability (PAT-D) for Obese Participants
-0.27 score on a scale
Interval -0.42 to -0.13
-0.08 score on a scale
Interval -0.24 to 0.08
-0.17 score on a scale
Interval -0.31 to -0.03

SECONDARY outcome

Timeframe: Baseline and 6 Months

Population: Full Analysis Set: Population consists of randomized participants, excluding participants who failed to take at least one dose of trial medication and had a very early withdrawal (first week after randomization) definitely not related to study medication and lacked any post randomization data. Participants with data available were included.

The SPPB was a series of tests designed to examine physical movements. Results of the SPPB included total gait speed score, total balance test score, and total chair stand score. The first tests examined balance (without the assistance of a cane or walker) with the feet in three different orientations, the second test examined gait speed, and the third tests involved standing from a Chair a number of times to test leg strength. A score of 0 was assigned to participants unable to perform the task. A summary score ranging from 0 (worst performers) to 12 (best performers) was calculated by adding sub scores from the walking speed, chair stands and balance tests. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Outcome measures

Outcome measures
Measure
Placebo
n=56 Participants
Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
175mg BIO101
n=58 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
350mg BIO101
n=55 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Change From Baseline to 6 Months in SPPB Total Score
1.1 score on a scale
Interval 0.5 to 1.6
1.00 score on a scale
Interval 0.4 to 1.5
0.9 score on a scale
Interval 0.3 to 1.5

SECONDARY outcome

Timeframe: Baseline and 6 Months

Population: Full Analysis Set: Population consists of randomized participants, excluding participants who failed to take at least one dose of trial medication and had a very early withdrawal (first week after randomization) definitely not related to study medication and lacked any post randomization data. This data represents overall disability score. Participants with data available were included.

The SarQoL was a sarcopenia-specific, self-administered, quality of life questionnaire designed for community-dwelling elderly study participants aged 65 years and older. The questionnaire contained 22 questions, which took approximately 10 minutes to complete. The questionnaire covered 7 domains: physical and mental health; locomotion; body composition; functionality; activities of daily living; leisure activities; and fears. Most questions are answered on a 4 point Likert scale. The total scoring of the SarQoL questionnaire ranges from 0 (worst imaginable health) to 100 (best imaginable health). A higher score reflected a higher quality of life. Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Outcome measures

Outcome measures
Measure
Placebo
n=45 Participants
Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
175mg BIO101
n=48 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
350mg BIO101
n=51 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Change From Baseline to 6 Months in Sarcopenia Quality of Life (SarQoL) Auto-Evaluation Questionnaire
8.05 score on a scale
Interval 4.95 to 11.14
5.60 score on a scale
Interval 2.43 to 8.78
5.83 score on a scale
Interval 2.79 to 8.87

SECONDARY outcome

Timeframe: Baseline and 6 Months

Population: Full Analysis Set: Population consists of randomized participants, excluding participants who failed to take at least one dose of trial medication and had a very early withdrawal (first week after randomization) definitely not related to study medication and lacked any post randomization data. Participants with data available were included.

The SCPT measured the ability to ascend and descend stairs and tests lower body strength and balance and measures time (in seconds) taken to ascend and descend a flight of stairs (10 steps with a 20 cm step height; a handrail was recommended). Step heights should have been suitable (between 16 and 20 cm). Data up to month 9 was used where 6 month data were unavailable for participants enrolled during the COVID-19 pandemic.

Outcome measures

Outcome measures
Measure
Placebo
n=31 Participants
Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
175mg BIO101
n=25 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
350mg BIO101
n=34 Participants
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Change From Baseline to 6 Months in Stair Climb Power Test (SCPT)
39.9 Seconds
Interval -46.4 to 126.3
32.4 Seconds
Interval -65.4 to 130.3
88.5 Seconds
Interval 5.1 to 171.8

Adverse Events

Placebo

Serious events: 10 serious events
Other events: 48 other events
Deaths: 1 deaths

175mg BIO101

Serious events: 10 serious events
Other events: 45 other events
Deaths: 0 deaths

350mg BIO101

Serious events: 4 serious events
Other events: 38 other events
Deaths: 1 deaths

Serious adverse events

Serious adverse events
Measure
Placebo
n=81 participants at risk
Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
175mg BIO101
n=75 participants at risk
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
350mg BIO101
n=74 participants at risk
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Cardiac disorders
AV block third degree
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Acute myocardial infarction
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Chest pain
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Ischemic stroke
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Recurrent cardiac decompensation
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Unstable angina
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Calculous cholecystitis
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Partial bowel obstruction
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Small bowel obstruction
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Toothache
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Infections and infestations
Cellulitis of leg
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Injury, poisoning and procedural complications
Ankle fracture
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Injury, poisoning and procedural complications
Fracture of intertrochanteric section of femur, closed
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Injury, poisoning and procedural complications
Snake bite
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma stage IV
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Nervous system disorders
Cerebrovascular accident
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Renal and urinary disorders
Bladder cancer recurrent
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Renal and urinary disorders
Urinary tract infection
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Renal and urinary disorders
Urolithiasis
1.2%
1/81 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease exacerbation
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Skin and subcutaneous tissue disorders
Shingles
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Surgical and medical procedures
Ankle fracture
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Surgical and medical procedures
Myocardial infarction
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Vascular disorders
Clot blood
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Vascular disorders
Ischemic stroke
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Vascular disorders
Orthostatic hypotension
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Infections and infestations
Coronavirus infection
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain tumor
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Investigations
General discomfort
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Chest pain
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).

Other adverse events

Other adverse events
Measure
Placebo
n=81 participants at risk
Placebo was taken orally, two capsules twice daily (BID), 12 hours apart, up to 9 months.
175mg BIO101
n=75 participants at risk
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
350mg BIO101
n=74 participants at risk
BIO101 was taken orally, two capsules BID, 12 hours apart, up to 9 months.
Cardiac disorders
AV block third degree
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Acute myocardial infarction
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Age indeterminate inferior myocardial infarction
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Atrial fibrillation
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Chest pain
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Chest pain - cardiac
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Coronary artery disease
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Dizziness
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Dizzy on standing
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Increased blood pressure
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Ischemic stroke
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Paroxysmal atrial fibrillation
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Recurrent cardiac decompensation
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Tachycardia
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Unstable angina
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Cardiac disorders
Vasovagal symptoms
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Blood and lymphatic system disorders
Anemia
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Ear and labyrinth disorders
Deafness temporary
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Ear and labyrinth disorders
Persistent postural-perceptual dizziness
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Endocrine disorders
Hyperparathyroidism
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Endocrine disorders
Hypoglycaemia
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Eye disorders
Central retinal vein occlusion
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Eye disorders
Corneal abrasion
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Eye disorders
Temporary vision loss
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Abdominal bloating
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Abdominal discomfort
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Acid reflux (esophageal)
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Alternation between constipation and diarrhea
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Bloated feeling
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Calculous cholecystitis
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Constipation
3.7%
3/81 • Number of events 3 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Diarrhea
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
4.0%
3/75 • Number of events 3 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Diarrhea recurrent
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Flatulence
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Food poisoning
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Frequent bowel movements
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
GERD
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Blood and lymphatic system disorders
International normalized ratio increased
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Blood and lymphatic system disorders
Prothrombin deficiency
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Blood and lymphatic system disorders
Thrombocytopenia
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Gastro-intestinal disorder NOS
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Gastroenteritis
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Gastrooesophageal reflux
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Ileus of intestine
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Loose stools
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Nausea
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
2.7%
2/75 • Number of events 3 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
2.7%
2/74 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Partial bowel obstruction
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Small bowel obstruction
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Stomach pain
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Tooth pain
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Toothache
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Gastrointestinal disorders
Vomited
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
General disorders
Decreased appetite
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
General disorders
General malaise
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
General disorders
Headache
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
General disorders
Hot flashes
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
General disorders
Mucosal sores
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
General disorders
Nausea
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
General disorders
Night sweats
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
General disorders
Post fall syndrome
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
General disorders
Tiredness
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Hepatobiliary disorders
Cholecystitis chronic
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Hepatobiliary disorders
Choledocholithiasis
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Hepatobiliary disorders
Cholelithiasis
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Hepatobiliary disorders
Gallbladder polyp
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Hepatobiliary disorders
Hemangioma of liver
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Hepatobiliary disorders
Hepatic lesion NOS
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Hepatobiliary disorders
Hepatic steatosis
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Hepatobiliary disorders
Impaired liver function
1.2%
1/81 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Hepatobiliary disorders
Steatosis hepatic
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Immune system disorders
Seasonal allergy
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Infections and infestations
Cellulitis of leg
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Infections and infestations
Common cold
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Infections and infestations
Flu
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
2.7%
2/75 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Infections and infestations
Influenza
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Infections and infestations
Influenza (epidemic)
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Infections and infestations
Respiratory tract infection bacterial
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Infections and infestations
Tooth infection
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Infections and infestations
Upper respiratory infection
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Injury, poisoning and procedural complications
Ankle fracture
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Injury, poisoning and procedural complications
Ankle injury
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Injury, poisoning and procedural complications
Dizziness
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Injury, poisoning and procedural complications
Fall
4.9%
4/81 • Number of events 4 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
2.7%
2/75 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
4.1%
3/74 • Number of events 3 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Injury, poisoning and procedural complications
Fracture of intertrochanteric section of femur, closed
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Injury, poisoning and procedural complications
Fractured nose
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Injury, poisoning and procedural complications
Laceration of head
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Injury, poisoning and procedural complications
Low back strain
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Injury, poisoning and procedural complications
Snake bite
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Investigations
Coronavirus test positive
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Investigations
GGT increased
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Investigations
Lipase increased
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Investigations
Triglycerides high
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Metabolism and nutrition disorders
Decreased appetite
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Metabolism and nutrition disorders
Electrolyte abnormality
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Metabolism and nutrition disorders
Hyperamylasemia
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Metabolism and nutrition disorders
Hypercalcemia
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Metabolism and nutrition disorders
Hypercholesteremia
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Metabolism and nutrition disorders
Hyperkalemia
1.2%
1/81 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Metabolism and nutrition disorders
Hyperlipasemia
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Metabolism and nutrition disorders
Worsening of diabetes
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Adhesive capsulitis of shoulder
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Arthralgia
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Arthritis
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
2.7%
2/74 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Arthropathy NOS
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Bursitis
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Fall
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
2.7%
2/74 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Fibula fracture
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Flare up of arthritis
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Foot fracture
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Fractured toe
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Gait tripping
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Leg cramps
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Leg pain
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Muscle cramps
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Muscle soreness
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Muscle spasms
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Muscle weakness
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Myalgia
1.2%
1/81 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Myalgia of lower extremities
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
2.7%
2/75 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Neck pain
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Osteoarthritis
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Osteoporosis
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Pain in hip
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
2.7%
2/75 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Pain in joint involving forearm
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Pain in leg
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Pain legs
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Painful R arm
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Pelvic bone pain
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Rib pain
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Rotator cuff injury
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Rotator cuff tendinitis
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Sarcopenia
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Shoulder pain
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Stiff neck
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Musculoskeletal and connective tissue disorders
Tendonitis
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Carcinoma basal cell
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma stage IV
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Nervous system disorders
Cerebrovascular accident
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Nervous system disorders
Dizziness
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Nervous system disorders
Essential tremor (hereditary)
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Nervous system disorders
Foot drop
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Nervous system disorders
Frontal headache
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Nervous system disorders
Head pain
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Nervous system disorders
Headache
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Nervous system disorders
Headache NOS
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Nervous system disorders
Insomnia
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Nervous system disorders
Lightheadedness
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Nervous system disorders
Movements disturbance NOS
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Nervous system disorders
Nerve pain
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Nervous system disorders
Sciatica
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Nervous system disorders
Tremor aggravated
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Nervous system disorders
Vascular parkinsonism
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Psychiatric disorders
Anorexia
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Psychiatric disorders
Anxiety depression
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Psychiatric disorders
Despondent
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Psychiatric disorders
Difficulty sleeping
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Renal and urinary disorders
Acute cystitis
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Renal and urinary disorders
Acute kidney injury
2.5%
2/81 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Renal and urinary disorders
Bilateral hydronephrosis
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Renal and urinary disorders
Bladder cancer recurrent
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Renal and urinary disorders
Creatine kinase increased
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Renal and urinary disorders
Cyst of kidney
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Renal and urinary disorders
Hematuria
2.5%
2/81 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Renal and urinary disorders
Urinary tract infection
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
4.0%
3/75 • Number of events 3 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Renal and urinary disorders
Urolithiasis
1.2%
1/81 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Reproductive system and breast disorders
Enlarged prostate (benign)
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Respiratory, thoracic and mediastinal disorders
Acute infective bronchitis
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Respiratory, thoracic and mediastinal disorders
Bronchitis
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
2.7%
2/74 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Respiratory, thoracic and mediastinal disorders
Coughing
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Respiratory, thoracic and mediastinal disorders
Bronchitis bacterial
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Respiratory, thoracic and mediastinal disorders
COPD
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Respiratory, thoracic and mediastinal disorders
Chest cold
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease exacerbation
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Respiratory, thoracic and mediastinal disorders
Cough
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Respiratory, thoracic and mediastinal disorders
Dysphagia
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Respiratory, thoracic and mediastinal disorders
Infective exacerbation of chronic obstructive airways disease
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Respiratory, thoracic and mediastinal disorders
Nose bleed
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Respiratory, thoracic and mediastinal disorders
Pharyngitis
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Respiratory, thoracic and mediastinal disorders
Pneumonia
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
2.7%
2/75 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Respiratory, thoracic and mediastinal disorders
Pulmonary fibrosis
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Respiratory, thoracic and mediastinal disorders
Shortness of breath
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Respiratory, thoracic and mediastinal disorders
Sleep apnea
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Respiratory, thoracic and mediastinal disorders
Upper respiratory infection
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Skin and subcutaneous tissue disorders
Allergic rash
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Skin and subcutaneous tissue disorders
Cellulitis of arm
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Skin and subcutaneous tissue disorders
Contact dermatitis
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Skin and subcutaneous tissue disorders
Dermatitis
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Skin and subcutaneous tissue disorders
Dry skin
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Skin and subcutaneous tissue disorders
Hair growth increased
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Skin and subcutaneous tissue disorders
Hairiness
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Skin and subcutaneous tissue disorders
Hidradenitis suppurativa
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Skin and subcutaneous tissue disorders
Itching
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Skin and subcutaneous tissue disorders
Itchy skin
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Skin and subcutaneous tissue disorders
Rash
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Skin and subcutaneous tissue disorders
Rash generalised
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Skin and subcutaneous tissue disorders
Shingles
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Skin and subcutaneous tissue disorders
Skin eruption
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Skin and subcutaneous tissue disorders
Skin irritation
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Skin and subcutaneous tissue disorders
Toe operation
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 3 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Social circumstances
Fall
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Social circumstances
Fatigue
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Surgical and medical procedures
Ankle fracture
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Surgical and medical procedures
Inguinal hernia repair
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Surgical and medical procedures
Myocardial infarction
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Surgical and medical procedures
Right cataract extraction
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Surgical and medical procedures
Tooth extraction
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Surgical and medical procedures
Wound
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Vascular disorders
Aortic aneurysm
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Vascular disorders
Clot blood
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Vascular disorders
Hypertension worsened
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Vascular disorders
Hypotension
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.3%
1/75 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Vascular disorders
Hypotension orthostatic
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Vascular disorders
Ischemic stroke
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Vascular disorders
Left deep vein thrombosis
1.2%
1/81 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Vascular disorders
Orthostatic hypotension
0.00%
0/81 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
1.4%
1/74 • Number of events 1 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
Vascular disorders
Syncope
1.2%
1/81 • Number of events 2 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/75 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).
0.00%
0/74 • Adverse events (AEs) were collected from the time of informed consent until the completion of the study or at the end-of-study visit (up to maximum of 9 months). All ongoing AEs were followed for an additional 30 days after the end-of-study visit.
An AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). Treatment-emergent adverse event (TEAE) is defined as any event that starts on or after the first dose date of study drug up to the last dose date + 6 weeks (date of first randomized study medication intake ≤AE onset date ≥ last dose date + 6 weeks).

Additional Information

Cendrine Tourette

Biophytis S.A.

Phone: +331 44 27 33 00

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place